And finally, we have also strengthened our balance sheet, having closed several simultaneous financings in September ...

Browse PMR's Wafer Vacuum Assembling Equipment Market Report Coverage from Different Publications: The global wafer vacuum ...

Projected 2024 Year-End Cash Position: Based on current operating plans, Invivyd expects to end 2024 with at least $65 million in cash and cash equivalents, based on anticipated growth of net product ...

This trial includes a 6-month open-label extension which is on track for completion in the first quarter of 2025. Our Phase 1 clinical pharmacology trial to evaluate our proprietary aerosol delivery ...

On October 15, 2024, Chemomab announced that on November 18, 2024, PSC expert Dr. Christopher Bowlus will be presenting a late-breaking oral presentation discussing the CM-101 PSC Phase 2 SPRING trial ...

Acquisition of Shares and Debt Claim against Cell C from Gramercy ...

She told of how the past six months have been a juggling act and she has found parenting as well as running her existing ...

WOBURN, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...

Separate your laundry into whites, lights, and darks. Wash whites separately to avoid yellowing, and wash darks separately to ...

Third Quarter 2024 Financial Results: Research and development expenses were approximately $931,000 for the three months ended September 2024 compared to approximately $1.9 million for the three ...

SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...

NYHA Class IV Approval: In August 2024, scPharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted approval for FUROSCIX, expanding the indication to include New York Heart ...